AbbVie Targets Mylan In Latest Effort To Shield Norvir Patents
AbbVie Inc. on Friday accused Mylan Pharmaceuticals Inc. of violating three of its patents by attempting to market a generic version of the HIV drug Norvir, according to a suit filed...To view the full article, register now.
Already a subscriber? Click here to view full article